TAG:
dianon systems
Specialty Labs and Dynacare Have Balance Sheet Differences
By Robert Michel | From the Volume VIII No. 5 – April 9, 2001 Issue
SINCE LAST FALL’S SUCCESSFUL IPOs (initial public offering) raised $92 million for Specialty Laboratories, Inc. and $50 million for Dynacare, Inc., the financial fortunes of the two lab companies have begun moving in different directions. Lab administrators and pa…
DIANON Systems, UroCor, Cytyc, Digene, McKesson HBOC, Abaton.com, Abbott
By Robert Michel | From the Volume VIII No. 4 – March 19, 2001 Issue
FEDERAL ATTORNEY SERVES SUBPOENA ON DIANON SYSTEMS NEWS BROKE LAST WEEK that DIANON Systems, Inc. had received a subpoena from the U.S. Attorney’s Office in Connecticut for documents relating to laboratory billing. Apparently “LabScam” is still alive …
Web-based Test Ordering Is A “Tough Nut To Crack”
By Robert Michel | From the Volume VIII No. 3 – February 26, 2001 Issue
CEO SUMMARY: Shifting office-based physicians to Web-accessed lab test ordering proved to be a daunting task for WebMD and its early competitors. Probably the most significant discovery is that modest capabilities of existing software technology and the lack of Internet broadband connecti…
DIANON Systems, IMPATH, Specialty Labs, Dynacare, Quest, LabCorp
By Robert Michel | From the Volume VIII No. 3 – February 26, 2001 Issue
DIANON & IMPATH REPORT 2000 EARNINGS TWO OF THE NATIONAL anatomic pathology companies reported fourth quarter earnings. Both DIANON Systems, Inc. and IMPATH, Inc. posted big gains in revenues and operating profits for 2000. At DIANON Systems, revenues r…
“Local” Anatomic Path Has Two Major Players
By Robert Michel | From the Volume VIII No. 2 – February 5, 2001 Issue
CEO SUMMARY: After a lot of money and much effort, the fledgling crop of companies wanting to consolidate and manage pathology group practices has narrowed into just two market leaders: AmeriPath and Pathology Service Associates. These two companies could not be more different in their go…
Competitive Dynamics In the Laboratory Testing Marketplace
By Robert Michel | From the Volume VII No. 18 – December 25, 2000 Issue
This section of the White Paper deals with the marketplace for laboratory services. For brevity and clarity, I will address five components: 1) independent commercial laboratories; 2) hospital-based laboratories; 3) esoteric, reference, and specialty testing laboratories; 4) anatomic pathology lab- o…
Year’s Ten Biggest Stories Reveal Modest Changes
By Robert Michel | From the Volume VII No. 17 – December 4, 2000 Issue
CEO SUMMARY: In many ways, 2000 was a relatively quiet year for laboratory organizations. This list of the ten biggest stories in the lab industry for 2000 demonstrates that the most innovative laboratory organizations in the United States are “raising the bar” for service and quality…
AmeriPath & InformDX Merging To Form Largest Anatomic Pathology Firm in U.S.
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: AmeriPath and InformDX shared several common elements in their respective business strategies. Both companies believe that pathology services are best delivered at the local level and benefit from the support of a national organization. Both companies believe that physicians …
Management Execution Makes a Difference
By R. Lewis Dark | From the Volume VII No. 14 – October 2, 2000 Issue
THERE’S PLENTY OF HOOROAR AND EXCITEMENT about skyrocketing stock prices for several public lab and pathology companies in 2000! But this crusty old curmudgeon has been around the investment industry too long to accept Wall Street’s new-found enthusiasm for clinical laboratories as definitive pr…
Successful Specialty IPO Can Open Door for Others
By Robert Michel | From the Volume VII No. 14 – October 2, 2000 Issue
CEO SUMMARY: It’s no secret that a handful of laboratory companies would like to complete an initial public offering (IPO). If Specialty Labs’ public offering goes well, expect these lab companies to bring their own stock offerings to the public equity markets. As the number of public…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized